ANCA associated glomerulonephritis
Conditions
Interventions
High risk group:Glucocorticoid + 4 doses of rituximab + 2 times of intravenous cyclophosphamide pulse therapy
Low and medium risk group:Glucocorticoid + 4 doses of rituximab
Sponsors
Children's Hospital Affiliated to Chongqing Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. The initial age of AAGN patients was 5-17 years old. The renal biopsy was completed and followed up in the hospital; 2. All enrolled children met the following inclusion criteria: (1) ANCA classification diagnostic criteria: patients who meet the classification algorithm of European Drug Administration (EMA) in 2007 or the definition of CHCC in 2012. Clinical classification includes: including microscopic polyangitis (MPA), granulomatosis with polyangitis (GPA) and eosinophilic granulomatosis with polyangitis (EGPA); (2) AAGN diagnostic criteria: ANCA vasculitis with any of the following: 1) Hematuria: gross hematuria or microscopic hematuria: three times of microscopic hematuria within a week: red blood cells in urine routine>3/high power field (HP) or > 17/ul (higher than the normal value, which can be adjusted according to the standards of each central laboratory); 2) Proteinuria: Those who meet any of the following requirements: routine urine protein is positive three times within a week; 24h urine protein content > 150 mg or urine protein/creatinine (mg/mg) > 0.2; Urinary microalbumin was higher than the normal value three times in a week; 3) Renal insufficiency: blood creatinine increased > basaline 10% or creatinine clearance decreased > 25%.
Exclusion criteria
Exclusion criteria: 1. The diagnosis depends on dialysis for more than 1 month, or the proportion of glomerular sclerosis at renal biopsy is >= 75%; 2. Patients with severe infection (such as diffuse peritonitis, severe pneumonia, cellulitis, active EB virus infection, active cytomegalovirus infection, hepatitis B virus infection, tuberculosis infection, fungal infection, etc.) and tumor patients; 3. Those with other primary or secondary renal diseases (such as IgA nephropathy, membranous nephropathy, anti-glomerular basement membrane nephritis, polycystic kidney disease, renal dysplasia, urinary tract malformation, etc.); 4. Parents or children refuse to join the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficiency; | — |
Countries
China
Contacts
Public ContactMo Wang
Children's Hospital Affiliated to Chongqing Medical University
Outcome results
None listed